TSH Biopharm Corporation Limited (TPEX:8432)

Market Cap	1.99B -14.5%
Revenue (ttm)	1.34B +20.9%
Net Income	139.26M +4.5%
EPS	3.62 +4.5%
Shares Out	38.40M
PE Ratio	14.34
Forward PE	n/a
Dividend	2.12 (3.98%)
Ex-Dividend Date	Jun 16, 2025

Volume	172,485
Average Volume	50,047
Open	52.60
Previous Close	53.30
Day's Range	51.50 - 52.70
52-Week Range	43.00 - 59.30
Beta	0.34
RSI	23.61
Earnings Date	Feb 24, 2026

About TSH Biopharm Corporation

TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid biopsy test designed for MRD detection and surveillance in stage I-III solid tumor patients; AlphaLiquid 100, a liquid biopsy test designed for patient...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 76
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 8432

Financial Performance

In 2024, TSH Biopharm Corporation's revenue was 1.12 billion, an increase of 37.59% compared to the previous year's 810.92 million. Earnings were 113.09 million, an increase of 82.44%.